Baris Esen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Baris Esen has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Yakup Kordan
Department of Urology Koc University Hospital Istanbul Turkiye
7 shared publicationsTarık Esen
Department of Urology Koc University Hospital Istanbul Turkiye
6 shared publicationsMehmet Onur Demirkol
Department of Nuclear Medicine Koc University Hospital Istanbul Turkiye
5 shared publicationsDerya Tilki
Koc Univ, Sch Med, Dept Urol, Istanbul, Turkiye
4 shared publications- Derya Tilki
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany
4 shared publications Hulya Seymen
Department of Nuclear Medicine Koc University Hospital Istanbul Turkiye
4 shared publications
Latest Publications
- 7 August 2026
- Published by Wiley in BJU International
- Vol. 138 (5) , 801-803
Impact of discordance between preoperative MRI and intraoperative ultrasound on surgical strategy in renal cell carcinoma with venous tumour thrombus
- 7 August 2026
- Published by Wiley in BJU International
- Vol. 138 (5) , 801-803
Impact of discordance between preoperative MRI and intraoperative ultrasound on surgical strategy in renal cell carcinoma with venous tumour thrombus
- Open Access
- 11 June 2026
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 7 (3) , 33
Regional Anesthesia for Open Radical Cystectomy: An Interesting Alternative, but for Whom? Comment on Peich et al. Open Radical Cystectomy Under Combined Spinal-Thoracic Epidural Anesthesia in High-Risk Patients: A Multicenter Retrospective Cohort Study. Soc. Int. Urol. J. 2026, 7, 32
In the current issue of Société Internationale d’Urologie Journal, Peich et al
- 11 June 2026
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 7 (3) , 33
Open AccessRegional Anesthesia for Open Radical Cystectomy: An Interesting Alternative, but for Whom? Comment on Peich et al. Open Radical Cystectomy Under Combined Spinal-Thoracic Epidural Anesthesia in High-Risk Patients: A Multicenter Retrospective Cohort Study. Soc. Int. Urol. J. 2026, 7, 32
In the current issue of Société Internationale d’Urologie Journal, Peich et al
- 1 December 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 8
Optimizing prostate biopsy: the role of targeted, regional, and systematic approaches
- 1 December 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 8
Optimizing prostate biopsy: the role of targeted, regional, and systematic approaches
- 6 September 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
Ureteroscopy in pediatric urolithiasis: techniques, challenges, and outcomes
- 6 September 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
Ureteroscopy in pediatric urolithiasis: techniques, challenges, and outcomes
- Open Access
- 27 February 2025
- Published by Wiley in The Prostate
- Vol. 85 (8) , 777-783
Impact of Pelvic Lymph Node Dissection on Early Oncological Outcomes in Intermediate‐Risk Prostate Cancer Patients With Node‐Negative PSMA PET
Background: PSMA PET/CT has previously shown superior performance in nodal staging of prostate cancer (PCa) and may be used to reduce the number of unnecessary PLND procedures. This study aims to assess the performance of PSMA PET/CT in nodal staging of intermediate‐risk prostate cancer and to evaluate the effect of PLND on oncological outcomes of intermediate‐risk prostate cancer patients with a negative PSMA PET/CT.Methods: A total of 308 patients with intermediate‐risk PCa who underwent PSMA PET/CT for nodal staging between January 2014 and July 2024 were included in the study. Patients who underwent PLND had higher PSA and higher rates of PIRADS‐5 and biopsy grade‐group 3 disease. A 1:1 propensity score matching was performed to eliminate patient characteristics differences between groups and 140 patients were included in the final analysis. PSA persistence rates ( ≥ 0.1 ng/dL) and biochemical recurrence (BCR; ≥ 0.2 ng/dL) rates after RP were recorded. Kaplan‐Meier curves were constructed to evaluate oncological outcomes. Log‐rank test was utilized to compare oncological outcomes in patients with and without PLND.Results: The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of PSMA PET/CT on nodal staging were 53.3%, 95%, 47.1%, and 96.1%, respectively. The NPV of PSMA PET/CT in patients with biopsy GG3 disease (96.3%) was similar to those with biopsy GG2 disease (95.6%). The median follow‐up after propensity score matching was 20.7 months. The 24‐month BCR‐free survival rates were 83.7% and 86.9% in the PLND‐RP group and RP‐only groups, respectively (p = 0.078).Conclusions: NPV of PSMA PET/CT in determining LNI was remarkable in patients with intermediate‐risk PCa and PLND was found to have no impact on oncological outcomes. Therefore PLND may be omitted to decrease surgery‐related complications in patients with intermediate‐risk PCa a negative PSMA PET/CT for nodal staging.
- 27 February 2025
- Published by Wiley in The Prostate
- Vol. 85 (8) , 777-783
Open AccessImpact of Pelvic Lymph Node Dissection on Early Oncological Outcomes in Intermediate‐Risk Prostate Cancer Patients With Node‐Negative PSMA PET
Background: PSMA PET/CT has previously shown superior performance in nodal staging of prostate cancer (PCa) and may be used to reduce the number of unnecessary PLND procedures. This study aims to assess the performance of PSMA PET/CT in nodal staging of intermediate‐risk prostate cancer and to evaluate the effect of PLND on oncological outcomes of intermediate‐risk prostate cancer patients with a negative PSMA PET/CT.Methods: A total of 308 patients with intermediate‐risk PCa who underwent PSMA PET/CT for nodal staging between January 2014 and July 2024 were included in the study. Patients who underwent PLND had higher PSA and higher rates of PIRADS‐5 and biopsy grade‐group 3 disease. A 1:1 propensity score matching was performed to eliminate patient characteristics differences between groups and 140 patients were included in the final analysis. PSA persistence rates ( ≥ 0.1 ng/dL) and biochemical recurrence (BCR; ≥ 0.2 ng/dL) rates after RP were recorded. Kaplan‐Meier curves were constructed to evaluate oncological outcomes. Log‐rank test was utilized to compare oncological outcomes in patients with and without PLND.Results: The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of PSMA PET/CT on nodal staging were 53.3%, 95%, 47.1%, and 96.1%, respectively. The NPV of PSMA PET/CT in patients with biopsy GG3 disease (96.3%) was similar to those with biopsy GG2 disease (95.6%). The median follow‐up after propensity score matching was 20.7 months. The 24‐month BCR‐free survival rates were 83.7% and 86.9% in the PLND‐RP group and RP‐only groups, respectively (p = 0.078).Conclusions: NPV of PSMA PET/CT in determining LNI was remarkable in patients with intermediate‐risk PCa and PLND was found to have no impact on oncological outcomes. Therefore PLND may be omitted to decrease surgery‐related complications in patients with intermediate‐risk PCa a negative PSMA PET/CT for nodal staging.
- 10 September 2024
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 43 (1) , 65.e9-65.e15
Natural history of PIRADS-2 lesions on serial multiparametric magnetic resonance imaging: Real-life data from an Academic Center
- 10 September 2024
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 43 (1) , 65.e9-65.e15
Natural history of PIRADS-2 lesions on serial multiparametric magnetic resonance imaging: Real-life data from an Academic Center
- Open Access
- 1 January 2024
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 50 (5) , 275-280
Revisiting Skull Metastases of Prostate Cancer at Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography Era: PSMA Uptake Characteristics and Oncological Outcomes
Objective: We aimed to evaluate prostate-specific membrane antigen (PSMA) uptake characteristics and the oncological outcomes in patients with skull metastases. Methods: The records of 345 serial PSMA positron emission tomography (PET)/computed tomography (CT) scans of 96 patients with metastatic prostate cancer (PCa) were evaluated retrospectively. Skull bone metastasis was detected in 18 patients (18/96, 18.7%), with a mean age of 72.4 Å} 9.1 years, and in 40 PSMA PET/CT scans (40/345, 11.6%). Involved skull bones, PSMA uptake characteristics, and CT counterparts of metastatic lesions were centrally reviewed. Prostate specific antigen (PSA) levels at the time of skull metastasis detection and PSMA-detected other metastatic lesions were recorded. Results: All patients with a skull metastasis showed multiple other metastatic bon lesions, and 6 (33.3%) had visceral metastasis. Seven (38.9%) patients had solitary skull lesions, whereas 11 (61.1%) had multiple skull metastases. Twenty-two out of 37 (59.5%) metastatic lesions had no CT counterpart. The median SUVmax was significantly higher in metastatic lesions with a CT counterpart (median 9.09 vs. 4.63, P = .018). At a median follow-up of 23.4 mo (interquartile range [IQR] 8.7-34.1) after detection of skull metastasis, 5 out of 11 (45.5%) hormone-sensitive and all castration-resistant patients died of PCa. The median survival of patients with castration-resistant disease was 9.92 months. Conclusion: The majority of PSMA-detected skull metastases did not show a CT counterpart, which may explain why skull metastases were rarely detected before the PSMA PET-era. In high-volume metastatic prostatic cancer cases, 68Ga-PSMA PET/CT imaging field including the vertex, may enhance the accuracy in detecting tumor extent and metabolic tumor volume. Cite this article as: Esen B, Falay O, Tarim K, et al. Revisiting skull metastases of prostate cancer at prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography era: PSMA uptake characteristics and oncological outcomes. Urol Res Pract. 2024;50(5):275-280.
- 1 January 2024
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 50 (5) , 275-280
Open AccessRevisiting Skull Metastases of Prostate Cancer at Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography Era: PSMA Uptake Characteristics and Oncological Outcomes
Objective: We aimed to evaluate prostate-specific membrane antigen (PSMA) uptake characteristics and the oncological outcomes in patients with skull metastases. Methods: The records of 345 serial PSMA positron emission tomography (PET)/computed tomography (CT) scans of 96 patients with metastatic prostate cancer (PCa) were evaluated retrospectively. Skull bone metastasis was detected in 18 patients (18/96, 18.7%), with a mean age of 72.4 Å} 9.1 years, and in 40 PSMA PET/CT scans (40/345, 11.6%). Involved skull bones, PSMA uptake characteristics, and CT counterparts of metastatic lesions were centrally reviewed. Prostate specific antigen (PSA) levels at the time of skull metastasis detection and PSMA-detected other metastatic lesions were recorded. Results: All patients with a skull metastasis showed multiple other metastatic bon lesions, and 6 (33.3%) had visceral metastasis. Seven (38.9%) patients had solitary skull lesions, whereas 11 (61.1%) had multiple skull metastases. Twenty-two out of 37 (59.5%) metastatic lesions had no CT counterpart. The median SUVmax was significantly higher in metastatic lesions with a CT counterpart (median 9.09 vs. 4.63, P = .018). At a median follow-up of 23.4 mo (interquartile range [IQR] 8.7-34.1) after detection of skull metastasis, 5 out of 11 (45.5%) hormone-sensitive and all castration-resistant patients died of PCa. The median survival of patients with castration-resistant disease was 9.92 months. Conclusion: The majority of PSMA-detected skull metastases did not show a CT counterpart, which may explain why skull metastases were rarely detected before the PSMA PET-era. In high-volume metastatic prostatic cancer cases, 68Ga-PSMA PET/CT imaging field including the vertex, may enhance the accuracy in detecting tumor extent and metabolic tumor volume. Cite this article as: Esen B, Falay O, Tarim K, et al. Revisiting skull metastases of prostate cancer at prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography era: PSMA uptake characteristics and oncological outcomes. Urol Res Pract. 2024;50(5):275-280.
- 11 October 2023
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48 (12) , e564-e569
Radioligand Therapy With 177Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer
Introduction: This study aimed to investigate the oncological outcomes and toxicity profile of 177Lu-PSMA-I&T radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC), as well as our initial experience in metastatic hormone-sensitive prostate cancer (mHSPC). Patients and Methods: A total of 38 consecutive patients with metastatic prostate cancer (33 mCRPC and 5 mHSPC) received 177Lu-PSMA-I&T RLT, with a median of 2 cycles per patient (range, 1–7). Response to RLT was evaluated based on prostate-specific antigen (PSA) changes and imaging response. Clinical progression-free survival and overall survival were used to report oncological outcomes. Toxicity was assessed using the Common Toxicity Criteria for Adverse Events criteria. Results: In mCRPC, 22 (69%), 18 (56%), and 11 (34%) patients achieved any PSA decline, PSA response of ≥30%, and PSA response of ≥50%, respectively. The clinical progression-free survival and overall survival after the first cycle of RLT were 6.3 and 21.4 months, respectively. In mHSPC, 177Lu-PSMA-I&T RLT resulted in excellent PSA response (93.0%–99.9%) in all cases. Clinical progression and cancer-related mortality occurred in only 1 case. Toxicity profile was favorable in both mHSPC and mCRPC. Conclusions: 177Lu-PSMA-I&T RLT demonstrated favorable PSA response (≥30%) in over half of the patients with mCRPC and excellent PSA response in all patients with mHSPC. Toxicity profile was favorable in both mHSPC and mCRPC settings. Further studies are needed to evaluate the role of 177Lu-PSMA-I&T RLT in the management of metastatic prostate cancer.
- 11 October 2023
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48 (12) , e564-e569
Radioligand Therapy With 177Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer
Introduction: This study aimed to investigate the oncological outcomes and toxicity profile of 177Lu-PSMA-I&T radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC), as well as our initial experience in metastatic hormone-sensitive prostate cancer (mHSPC). Patients and Methods: A total of 38 consecutive patients with metastatic prostate cancer (33 mCRPC and 5 mHSPC) received 177Lu-PSMA-I&T RLT, with a median of 2 cycles per patient (range, 1–7). Response to RLT was evaluated based on prostate-specific antigen (PSA) changes and imaging response. Clinical progression-free survival and overall survival were used to report oncological outcomes. Toxicity was assessed using the Common Toxicity Criteria for Adverse Events criteria. Results: In mCRPC, 22 (69%), 18 (56%), and 11 (34%) patients achieved any PSA decline, PSA response of ≥30%, and PSA response of ≥50%, respectively. The clinical progression-free survival and overall survival after the first cycle of RLT were 6.3 and 21.4 months, respectively. In mHSPC, 177Lu-PSMA-I&T RLT resulted in excellent PSA response (93.0%–99.9%) in all cases. Clinical progression and cancer-related mortality occurred in only 1 case. Toxicity profile was favorable in both mHSPC and mCRPC. Conclusions: 177Lu-PSMA-I&T RLT demonstrated favorable PSA response (≥30%) in over half of the patients with mCRPC and excellent PSA response in all patients with mHSPC. Toxicity profile was favorable in both mHSPC and mCRPC settings. Further studies are needed to evaluate the role of 177Lu-PSMA-I&T RLT in the management of metastatic prostate cancer.
- 3 September 2023
- Published by Wiley in The Prostate
- Vol. 84 (1) , 32-38
The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer
Introduction and Objectives: To investigate the additive role of prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) independent from multiparametric magnetic resonance imaging (mpMRI) and clinical‐pathological parameters to predict pathological upgrading in patients with ISUP grade group (GG) 1 prostate cancer (PCa) at prostate biopsy.Materials and Methods: A total of 41 patients who underwent robotic radical prostatectomy (RP) for GG1 disease at prostate biopsy with preoperative PSMA PET/CT and mpMRI images available for central review were included in the study. Univariate and multivariate logistic regression analyses were performed to determine the independent predictors of pathological upgrading (GG ≥ 2).Results: Final RP pathology revealed upgrading in 26 patients (65.9%); to GG 2 disease in 25 cases and GG 4 disease in one case. International Society of Urological Pathology (ISUP) upgrading rates for prostate imaging‐reporting and data system (PIRADS)‐5, PIRADS‐4, and PIRADS ≤ 3 lesions were 78%, 74%, and 38%, respectively. Fourteen out of 15 (93.3%) patients with an SUVmax ≥ 5.6 and all patients with an SUVmax ≥ 6.5 (n = 10) had pathological upgrading. The upgrading rate in patients with SUV < 5.6 was 46.2% (12/26). Intraprostatic SUVmax ≥ 5.6 was found as the only independent predictor of pathological upgrading in multivariate analysis.Conclusion: High prostatic PSMA uptake was found to be a very reliable predictor of pathological upgrading, but low PSMA uptake cannot exclude pathological upgrading. Intraprostatic PSMA uptake along with previously known mpMRI and biopsy‐related parameters should be considered when making a treatment decision in patients with GG1 PCa at prostate biopsy.
- 3 September 2023
- Published by Wiley in The Prostate
- Vol. 84 (1) , 32-38
The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer
Introduction and Objectives: To investigate the additive role of prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) independent from multiparametric magnetic resonance imaging (mpMRI) and clinical‐pathological parameters to predict pathological upgrading in patients with ISUP grade group (GG) 1 prostate cancer (PCa) at prostate biopsy.Materials and Methods: A total of 41 patients who underwent robotic radical prostatectomy (RP) for GG1 disease at prostate biopsy with preoperative PSMA PET/CT and mpMRI images available for central review were included in the study. Univariate and multivariate logistic regression analyses were performed to determine the independent predictors of pathological upgrading (GG ≥ 2).Results: Final RP pathology revealed upgrading in 26 patients (65.9%); to GG 2 disease in 25 cases and GG 4 disease in one case. International Society of Urological Pathology (ISUP) upgrading rates for prostate imaging‐reporting and data system (PIRADS)‐5, PIRADS‐4, and PIRADS ≤ 3 lesions were 78%, 74%, and 38%, respectively. Fourteen out of 15 (93.3%) patients with an SUVmax ≥ 5.6 and all patients with an SUVmax ≥ 6.5 (n = 10) had pathological upgrading. The upgrading rate in patients with SUV < 5.6 was 46.2% (12/26). Intraprostatic SUVmax ≥ 5.6 was found as the only independent predictor of pathological upgrading in multivariate analysis.Conclusion: High prostatic PSMA uptake was found to be a very reliable predictor of pathological upgrading, but low PSMA uptake cannot exclude pathological upgrading. Intraprostatic PSMA uptake along with previously known mpMRI and biopsy‐related parameters should be considered when making a treatment decision in patients with GG1 PCa at prostate biopsy.